The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This stock page is the Follow view. The Build view lets your agent query PRLD owners, fund changes, insider filings, and source links through REST or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/PRLD"
Use Arkolith to show who owns PRLD, which funds added or reduced it, and which SEC filings prove each claim.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | $37.3M | 10.9M | —Held | Q1 2026 | |
| 2 | BAKER BROS. ADVISORS LP | $34.6M | 10.1M | —Held | Q1 2026 | |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $4.2M | 1.2M | ▲New +1.2M sh | Q1 2026 | |
| 4 | VANGUARD GROUP INC | $4.1M | 1.4M | ▲+42% Added · +421K sh | Q4 2025 | |
| 5 | EcoR1 Capital, LLC | $3.2M | 947K | ▲New +947K sh | Q1 2026 | |
| 6 | TWO SIGMA INVESTMENTS, LP | $3.2M | 924K | ▲+17% Added · +135K sh | Q1 2026 | |
| 7 | MILLENNIUM MANAGEMENT LLC | $1.3M | 383K | ▲+153% Added · +232K sh | Q1 2026 | |
| 8 | MARSHALL WACE, LLP | $1.2M | 359K | ▲+31% Added · +85K sh | Q1 2026 | |
| 9 | MORGAN STANLEY | $1.1M | 322K | ▼−3.8% Reduced · −13K sh | Q1 2026 | |
| 10 | BlackRock, Inc. | $1.1M | 322K | ▲+21% Added · +56K sh | Q1 2026 | |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | $1.0M | 302K | ▲+11% Added · +30K sh | Q1 2026 | |
| 12 | RENAISSANCE TECHNOLOGIES LLC | $941K | 275K | ▲+1.4% Added · +4K sh | Q1 2026 | |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $916K | 268K | ▲+97% Added · +132K sh | Q1 2026 | |
| 14 | GOLDMAN SACHS GROUP INC | $809K | 236K | ▲+101% Added · +119K sh | Q1 2026 | |
| 15 | JANE STREET GROUP, LLC | $660K | 193K | ▲+74% Added · +82K sh | Q1 2026 | |
| 16 | VANGUARD FIDUCIARY TRUST CO | $538K | 157K | ▲New +157K sh | Q1 2026 | |
| 17 | ADAR1 Capital Management, LLC | $523K | 153K | ▲New +153K sh | Q1 2026 | |
| 18 | STATE STREET CORP | $473K | 138K | ▲+8.6% Added · +11K sh | Q1 2026 | |
| 19 | CITADEL ADVISORS LLC | $425K | 124K | ▲New +124K sh | Q1 2026 | |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | $373K | 109K | ▲+137% Added · +63K sh | Q1 2026 | |
| 21 | UBS Group AG | $221K | 65K | ▲35× Added · +63K sh | Q1 2026 | |
| 22 | XTX Topco Ltd | $196K | 57K | ▲+14% Added · +7K sh | Q1 2026 | |
| 23 | BANK OF AMERICA CORP /DE/ | $193K | 57K | ▲+476% Added · +47K sh | Q1 2026 | |
| 24 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | $183K | 54K | —Held | Q1 2026 | |
| 25 | NORTHERN TRUST CORP | $171K | 50K | —Held | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 9, 2026 | Sandor Victor | Director | Grant (A) | 38K | $0 |
| Jun 9, 2026 | Babler Martin | Director | Grant (A) | 38K | $0 |
| Jun 9, 2026 | Dorton Katina | Director | Grant (A) | 38K | $0 |
| Jun 9, 2026 | Bonita David P | Director, 10% Owner | Grant (A) | 38K | $0 |
| Jun 9, 2026 | FRIEDMAN PAUL A | Director | Grant (A) | 38K | $0 |
| Jun 9, 2026 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Grant (A) | 38K | $0 |
| Jun 9, 2026 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Grant (A) | 38K | $0 |
| Feb 4, 2026 | Vaddi Krishna | CEO, Director | Grant (A) | 837K | $0 |
| Feb 4, 2026 | Lim Bryant David | CLO, CFO, Corp Sec. | Grant (A) | 275K | $0 |
| Feb 4, 2026 | Scherle Peggy | Chief Scientific Officer | Grant (A) | 230K | $0 |
| Feb 4, 2026 | Combs Andrew | Chief Chemistry Officer | Grant (A) | 230K | $0 |
| Nov 5, 2025 | Sandor Victor | Director | Grant (A) | 121K | $0 |
| Company | Co-held by | Combined value |
|---|---|---|
| ELI LILLY & COLLY | 9 funds | $1.1B |
| CELCUITY INCCELC | 9 funds | $956.8M |
| CRINETICS PHARMACEUTICALS INCRNX | 9 funds | $292.0M |
| KINIKSA PHARMACEUTICALS INTEKNSA | 9 funds | $230.9M |
| TERNS PHARMACEUTICALS INC430 | 9 funds | $191.1M |
| MBX BIOSCIENCES INCMBX | 9 funds | $160.1M |
| ORIC PHARMACEUTICALS INCORIC | 9 funds | $156.9M |
| CORVUS PHARMACEUTICALS INCCRVS | 9 funds | $113.0M |
| REPLIMUNE GROUP INCREPL | 9 funds | $96.2M |
| ALUMIS INCALMS | 9 funds | $72.5M |
| RELAY THERAPEUTICS INCRLAY | 9 funds | $41.4M |
| JADE BIOSCIENCES INCJBIO | 9 funds | $33.7M |
Ranked by how many of PRLD's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for PRLD. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.